Chroma, a genomic medicine company pioneering single-dose epigenetic editing therapeutics founded on UCSF research discovered by Luke Gilbert, PhD, and Jonathan Weissman, PhD., today announced the completion of a $135 million Series B financing. The financing will support the advancement of Chroma's therapeutic programs toward the clinic, and continued investment in the company's core epigenetic editing platform.
